Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. Endo International plc
  6. News
  7. Summary
    ENDPQ   IE00BJ3V9050

ENDO INTERNATIONAL PLC

(ENDPQ)
  Report
Delayed OTC Markets  -  03:58 2022-12-05 pm EST
0.0926 USD   -2.09%
12/02Endo International Plc : Other Events (form 8-K)
AQ
11/22Factbox-Pharmacies, drug companies settle lawsuits over U.S. opioid crisis
RE
11/09ENDO INTERNATIONAL PLC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Factbox-Pharmacies, drug companies settle lawsuits over U.S. opioid crisis

11/22/2022 | 12:24pm EST
FILE PHOTO: Tablets of the opioid-based Hydrocodone at a pharmacy in Portsmouth

(Reuters) - The sprawling, five-year-long litigation over the U.S. opioid crisis appears to be entering its final phase with finalized agreements by Teva Pharmaceutical Industries Ltd and AbbVie Inc.

There are tentative agreements by CVS Health Corp, Walgreens Boots Alliance Inc and Walmart Inc to settle with state, local and tribal governments.

Smaller pharmacy operators, including Rite Aid Corp and Kroger Co, have yet to settle. But the deal by the nation's largest retail pharmacies adds to previous settlements with drugmakers and the largest U.S. distributors. The following are major companies that were accused of contributing to the crisis, and settlements or judgments involving those companies. All have denied the allegations.

PHARMACY CHAINS

CVS, Walgreens and Walmart:

-Agreed in principle to pay a combined $13.8 billion to resolve claims against them nationwide.

-Ordered in August to pay a combined $650.6 million to two Ohio counties after a jury found them liable for fueling opioid addiction there.

-Reached separate settlements with Florida, with CVS agreeing in March to pay $484 million, Walgreens agreeing in May to pay $683 million and Walmart agreeing last month to pay $215 million. Some of Walgreens' settlement with Florida has also been included in the nationwide deal announced this week.

-CVS and Walmart, but not Walgreens, settled with West Virginia for $82.5 million and $65 million, respectively.

-All three pharmacy chains along with Rite Aid agreed in July 2021 to pay a combined $26 million to settle claims by the New York counties of Suffolk and Nassau.

DRUG DISTRIBUTORS

Cardinal Health Inc, AmerisourceBergen Corp and McKesson Corp, the national largest drug wholesalers:

-Agreed in July 2021 to a proposed $21 billion nationwide settlement, which was finalized in February.

-Reached separate deals with plaintiffs that declined to join the nationwide settlement, including $518 million for Washington state in May, $250 million for Oklahoma in June and $400 million for West Virginia cities and counties in August.

-Settled in February with hundreds of Native American tribes for $440 million, on top of a $75 million deal with the Cherokee Nation in September 2021.

-Settled in 2019 with two Ohio counties for $215 million on the eve of trial.

-Prevailed in June after a non-jury trial against claims by a West Virginia city and county that had sought $2.5 billion.

-McKesson agreed to pay $141 million to Alabama in April.

DRUG MANUFACTURERS

Purdue Pharma LP:

-Agreed in May to a nationwide $6 billion settlement as part of its bankruptcy plan, funded by its Sackler family owners, who will be shielded from future liability. The deal cannot be finalized unless a federal appeals court revives the Sacklers' legal shield, which was ruled illegal by a federal judge.

-In November 2020, entered a guilty plea to three criminal counts for violating a federal anti-kickback law, defrauding the United States and violating the Food, Drug and Cosmetic Act.

Johnson & Johnson

-Agreed in July 2021 to a proposed $5 billion nationwide settlement, which was finalized in February.

-Reached separate settlements with holdout states, including $40.5 million for New Hampshire in September, $70.3 million for Alabama in April and $99 million for West Virginia in April.

-The Oklahoma Supreme Court in November 2021 overturned a $465 million judgment the state won following a 2019 trial.

Teva Pharmaceutical Industries Ltd

-In November, finalized claims nationwide for $4.25 billion, some of which is to be paid as a supply of the overdose-reversing drug naloxone. The deal includes previously announced settlements with West Virginia, Texas, Florida, Rhode Island, Louisiana and San Francisco.

-Has agreed to pay an additional $100 million to settle claims by Native American tribes.

-Found liable by a New York jury for fueling opioid addiction in that state, with the dollar amount to be determined at a later trial.

AbbVie Inc

-In November, finalized a $2.37 billion nationwide settlement resolving claims against Allergan, a company it acquired in 2020. The deal includes previous agreements with states including New York.

Endo International Plc

-Reached a $450 million settlement with more than 30 states as part of a bankruptcy filing in August.

-Before bankruptcy reached settlements with individual plaintiffs including $35 million for two Tennessee counties in July 2021, $50 million for New York and two of its counties in September 2021, $63 million for Texas in December 2021 and $65 million for Florida in January.

Mallinckrodt Plc

-Reached a $1.7 billion nationwide settlement as part of its bankruptcy reorganization plan, approved in February.

-A California judge last November following a non-jury trial rejected claims by several large counties against J&J, Teva, Endo and AbbVie.

(Reporting by Brendan Pierson and Dietrich Knauth in New York, Nate Raymond in Boston and Tom Hals in Wilmington, Delaware; Editing by Bill Berkrot and Lisa Shumaker)

By Brendan Pierson


ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE INC. 0.17% 163.94 Delayed Quote.21.08%
AMERISOURCEBERGEN CORPORATION -1.56% 171.28 Delayed Quote.30.93%
CARDINAL HEALTH, INC. -1.73% 79.48 Delayed Quote.57.08%
CVS HEALTH CORPORATION -0.56% 102.01 Delayed Quote.-0.56%
ENDO INTERNATIONAL PLC -2.09% 0.0926 Delayed Quote.-97.54%
INDIVIOR PLC -0.12% 1718 Delayed Quote.33.70%
KROGER CO. (THE) -3.15% 46.07 Delayed Quote.5.10%
MCKESSON CORPORATION -1.14% 382.44 Delayed Quote.55.63%
RECKITT BENCKISER GROUP PLC -0.83% 5988 Delayed Quote.-5.58%
RITE AID CORPORATION -3.52% 4.93 Delayed Quote.-65.21%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED 0.00% 29.85 End-of-day quote.10.76%
WALGREENS BOOTS ALLIANCE, INC. -0.65% 41.21 Delayed Quote.-20.99%
WALMART INC. -1.02% 151.65 Delayed Quote.5.90%
All news about ENDO INTERNATIONAL PLC
12/02Endo International Plc : Other Events (form 8-K)
AQ
11/22Factbox-Pharmacies, drug companies settle lawsuits over U.S. opioid crisis
RE
11/09ENDO INTERNATIONAL PLC Management's Discussion and Analysis of Financial Condition and..
AQ
11/09Endo International : ENDP Q3 2022 Slides
PU
11/09Endo International plc Reports Earnings Results for the Third Quarter and Nine Months E..
CI
11/09Endo reports third-quarter 2022 financial results
PR
11/02Factbox-Pharmacies, drug companies in litigation over role in U.S. opioid crisis
RE
11/01CVS, Walmart, Walgreens agree to pay $13.8 bln to settle U.S. opioid claims
RE
10/27Endo International plc and SMSNA Launches App to Provide Peyronie's Disease Self-Assess..
CI
10/27Endo and SMSNA Launch App to Provide Peyronie's Disease Self-Assessment Tool
PR
More news
Analyst Recommendations on ENDO INTERNATIONAL PLC
More recommendations
Financials (USD)
Sales 2021 2 993 M - -
Net income 2021 -613 M - -
Net Debt 2021 6 812 M - -
P/E ratio 2021 -1,43x
Yield 2021 -
Capitalization 22,2 M 22,2 M -
EV / Sales 2020 3,04x
EV / Sales 2021 2,57x
Nbr of Employees 3 103
Free-Float 99,2%
Chart ENDO INTERNATIONAL PLC
Duration : Period :
Endo International plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENDO INTERNATIONAL PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Last Close Price 0,09 $
Average target price 1,00 $
Spread / Average Target 980%
Managers and Directors
Blaise A Coleman President, Chief Executive Officer & Director
Mark Bradley Chief Financial Officer & Executive Vice President
Mark G. Barberio Chairman
Ruth Thorpe Chief Information Officer
James Patrick Tursi Executive VP-Global Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ENDO INTERNATIONAL PLC-97.54%22
JOHNSON & JOHNSON4.57%467 679
ELI LILLY AND COMPANY35.67%356 089
ABBVIE INC.21.08%289 331
NOVO NORDISK A/S22.04%285 887
PFIZER, INC.-13.78%285 774